Table 1.
Literature review of ER, PR and HER-2 discordance between primary tumours and corresponding metastatic sites
| Cases | Metastatic sites | Type of analysis | ER (%) | PR (%) | HER-2 (%) | |
|---|---|---|---|---|---|---|
| Andersen 1988 [10] | 143 | ALM/DM | Biomarkers reassessment | 10 | ||
| Li 1994 [17] | 83 | LR/DM | Biomarkers reassessment | 29 | 44 | |
| Van Agthoven 1995 [28] | 26 | ALM | Biomarkers reassessment | 0 | ||
| Johnston 1995 [8] | 34 | LR | Biomarkers reassessment | 23 | 26 | |
| Kuukasjarvi 1996 [16] | 50 | LR | Biomarkers reassessment | 24 | 24 | |
| Shimizu 2000 [24] | 21 | LR/DM | Biomarkers reassessment | 25 | 30 | 0 |
| Zheng 2001 [30] | 52 | ALM | Biomarkers reassessment | 6 | ||
| Tanner 2001 [6] | 45 | LR/DM | Biomarkers reassessment | 0 | ||
| Simon 2001 [25] | 125 | ALM | Biomarkers reassessment | 3 | ||
| Gancberg 2002 [1] | 100 | DM | Biomarkers reassessment | 6 | ||
| Vincent-Salomon 2002 [29] | 44 | DM | Biomarkers reassessment | 4 | ||
| Edgerton 2003 [13] | 113 | LR/DM | Biomarkers reassessment | 20 | ||
| Iguchi 2003 [15] | 87 | ALM | Biomarkers reassessment | 24 | ||
| Carlsson 2004 [12] | 47 | ALM | Biomarkers reassessment | 0 | ||
| Regitnig 2004 [21] | 31 | DM | Biomarkers reassessment | 10 | ||
| Gong 2005 [2] | 60 | ALM/LR/DM | Biomarkers reassessment | 3 | ||
| Zidan 2005 [7] | 58 | LR/DM | Biomarkers reassessment | 14 | ||
| Lower 2005 [20] | 200 | LR/DM | Reports review | 30 | 39 | |
| Tapia 2007 [26] | 105 | DM | Biomarkers reassessment | 3 | ||
| Guarneri 2008 [3] | 75 | LR/DM | Reports review | 22 | 36 | 16 |
| Gomez-Fernandez 2008 [14] | 278 | LR/DM | Biomarkers reassessment | 3 | ||
| Santinelli 2008 [22] | 119 | ALM/LR/DM | Biomarkers reassessment | 14 | ||
| Broom 2009 [11] | 100 | DM | Reports review | 18 | 37 | 5 |
| Simmons 2009 [5] | 29 | DM | Biomarkers reassessment | 12 | 28 | 8 |
| Liedtke 2009 [18] | 211 | LR/DM | Reports review | 18 | 40 | 14 |
| Idirisinghe 2010 [4] | 117 | LR/DM | Biomarkers reassessment | 16 | 38 | 5 |
| Sari 2010 [23] | 78 | LR/DM | Biomarkers reassessment | 36 | 54 | 15 |
| Thompson 2010 [27] | 137 | LR/DM | Biomarkers reassessment | 10 | 25 | 3 |
| Amir 2010 [9] | 271 | LR/DM | Biomarkers reassessment | 13 | 34 | 5 |
| Locatelli 2010 [19] | 255 | DM (liver) | Reports review | 14 | 48 | 14 |
ALM axillary lymph node metastases, LR local recurrences, DM distant metastases, ER estrogen receptor, PR progesterone receptor